REWIRE CLOUD

REWIRE CLOUD is a first‑in‑class, rewritable theranostic platform that converts inert nanocarriers into an in‑vivo operating system programmable by focused ultrasound. By letting clinicians “flash” new genomic payloads up to eight times inside the same circulating nanoparticle, the system promises to turn static, one‑shot therapies into adaptive treatment loops that co‑evolve with a tumour’s mutational escape routes. The approach addresses three historic bottlenecks at once: real‑time dosing control, longitudinal pharmacovigilance, and the spiralling cost of personalised biologics. In so doing, it sets a new benchmark for precision oncology devices that are both minimally invasive and continuously upgradeable. nical Problem & Market Need Metastatic melanoma and other fast‑mutating solid tumours routinely outpace conventional antibody–drug conjugates and cell therapies, whose manufacturing lead‑times exceed the tumour’s own evolutionary clock. Current salvage regimens can cost >$300k per patient and still deliver sub‑20 % five‑year survival once resistance emerges. A low‑volume, ultrasound‑programmable nanoparticle that can be restocked with new CRISPR guides or siRNA payloads inside the bloodstream could slash both cost and mortality, unlocking a global addressable market projected at US $6 billion by 2030 for adaptive oncology alone.